VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ASNDAscendis Pharma A/S
$230.83$14.3B
Research
OverviewAnalysis
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksASNDPrice Target
ASND logo

Ascendis Pharma A/S (ASND) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 25 analysts

24.6% Below Target

ASND trades 24.6% below Wall Street's consensus target of $287.50.

Current Price$230.83
Average Target$287.50
Target
Current
Low$250.00
Median$267.50
High$345.00

Analyst Target Range

Forward P/E17.1x
(Fair)
PEG Ratio—
Implied Growth+72.0%
(High Growth)
Analyst Spread33.0%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$230.83
Consensus$287.50
High$345.00
Low$250.00

Consensus Scenario Assumptions

The base valuation assumes ASND achieves its forward estimates and maintains a stable P/E multiple of 17.1x. This scenario reflects the blended consensus of 25 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 25 published analyst recommendations for ASND

23/25 analysts are bullish
+46
BearishBullish
Weighted analyst sentiment score based on 25 ratings
ConsensusBuy
Coverage25 Analysts
Net Score+46
Bull / Bear92% / 0%
Strong Buy00%
Buy2392%
Hold28%
Sell00%
Strong Sell00%
Strong Buy
00%
Buy
2392%
Hold
28%
Sell
00%
Strong Sell
00%
Recommendation Mix92% Buy · 8% Hold · 0% Sell
Buy (23)Hold (2)Sell (0)

ASND Price Target Analysis

Updated June 21, 2026

As of June 21, 2026, Ascendis Pharma A/S (ASND) has a Wall Street consensus price target of $287.50, based on estimates from 25 covering analysts. With the stock currently trading at $230.83, this represents a potential upside of +24.6%. The company has a market capitalization of $14.26B.

Analyst price targets range from a low of $250.00 to a high of $345.00, representing a 33% spread in expectations. The median target of $267.50 differs from the mean, suggesting potential outlier estimates.

The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, ASND trades at a trailing P/E of -55.4x and forward P/E of 17.1x. Analysts expect EPS to grow +72.0% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $63.49, with bear and bull scenarios of $40.00 and $83.66 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+19.1%
Industry Consensus
Avg Forward P/E
27.8x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
IONS logo
IONSIonis Pharmaceuticals, Inc.
$12.2B$74.12$109.44
+47.7%
Buy—32
INCY logo
INCYIncyte Corporation
$19.6B$98.22$109.80
+11.8%
Buy13.0x44
ALKS logo
ALKSAlkermes plc
$7.5B$44.99$49.50
+10.0%
Buy—28
JAZZ logo
JAZZJazz Pharmaceuticals plc
$14.1B$224.66$257.44
+14.6%
Buy8.9x48
ACAD logo
ACADACADIA Pharmaceuticals Inc.
$3.7B$21.62$33.67
+55.7%
Buy55.6x37
RARE logo
RAREUltragenyx Pharmaceutical Inc.
$2.7B$27.44$48.36
+76.2%
Buy—33
AMRN logo
AMRNAmarin Corporation plc
$333M$16.03$2.17
-86.5%
Hold—18
CLDX logo
CLDXCelldex Therapeutics, Inc.
$2.2B$32.43$49.00
+51.1%
Buy—19
KRYS logo
KRYSKrystal Biotech, Inc.
$10.3B$348.06$336.40
-3.4%
Buy44.9x17
ACHC logo
ACHCAcadia Healthcare Company, Inc.
$2.3B$24.87$28.33
+13.9%
Buy16.5x25

ASND — Frequently Asked Questions

Quick answers to the most common questions about buying ASND stock.

What is the ASND stock price target for 2026?

The consensus Wall Street price target for ASND is $287.5, representing 24.6% upside from the current price of $230.83. With 25 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is ASND a buy, sell, or hold?

ASND has a consensus rating of "Buy" based on 25 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $287.5 implies 24.6% upside from current levels.

Is ASND stock overvalued or undervalued?

With a forward P/E of 17.0923x, ASND trades at a relatively low valuation. The consensus target of $287.5 implies 24.6% appreciation, suggesting meaningful undervaluation.

How high can ASND stock go?

The most bullish Wall Street analyst has a price target of $345 for ASND, while the most conservative target is $250. The consensus of $287.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $84 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover ASND stock?

ASND is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 23 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the ASND stock forecast?

The 12-month ASND stock forecast based on 25 Wall Street analysts shows a consensus price target of $287.5, with estimates ranging from $250 (bear case) to $345 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $63, with bear/bull scenarios of $40/$84.

What is ASND's fair value based on fundamentals?

Our quantitative valuation model calculates ASND's fair value at $63 (base case), with a bear case of $40 and bull case of $84. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.

What is ASND's forward P/E ratio?

ASND trades at a forward P/E ratio of 17.1x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy ASND stock?

Wall Street analysts are very optimistic on ASND, with a "Buy" consensus rating and $287.5 price target (24.6% upside). 23 of 25 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do ASND price targets vary so much?

ASND analyst price targets range from $250 to $345, a 33% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $287.5 consensus represents the middle ground. Our model's $40-$84 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into ASND consensus models and risk factors.

View Analysis

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare